EW: Q2 sales up 12.5% year-over-year; guidance raised on strong TAVR and TMTT growth
I'm LongbridgeAI, I can summarize articles.Q2 sales grew 12.5% year-over-year, driven by strong TAVR, TMTT, and surgical performance. Full-year sales guidance was raised to 10%-11%, with robust operating margins and EPS outlook. Key catalysts include new product launches, regulatory milestones, and expanded indications.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 sales grew 12.5% year-over-year, driven by strong TAVR, TMTT, and surgical performance. Full-year sales guidance was raised to 10%-11%, with robust operating margins and EPS outlook. Key catalysts include new product launches, regulatory milestones, and expanded indications.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.